<div id="readability-page-1">An announcement from Akeso, Inc. ( (HK:9926) ) is now available.Akeso, Inc. has authorized the use of up to HK$200 million of its existing cash resources to purchase its own shares on the open market through the trustee of its 2021 restricted share unit scheme, arguing that the current share price undervalues the company’s intrinsic worth and business prospects. The move is framed as a signal of confidence from the board and management and is intended to enhance shareholder value by taking advantage of what it sees as a mispriced stock.In a parallel show of support, Akeso’s chairwoman and chief executive, along with several executive directors and the chief financial officer, plan to buy additional shares in the market worth up to a combined HK$50 million using their personal funds. Their planned purchases, subject to regulatory compliance, underscore their belief in the Group’s long-term investment value, robust R&amp;D capabilities and ability to sustain innovation, while the company cautions investors to exercise care when trading its securities. The most recent analyst rating on (HK:9926) stock is a Hold with a HK$130.00 price target. To see the full list of analyst forecasts on Akeso, Inc. stock, see the HK:9926 Stock Forecast page. <div> More about Akeso, Inc. Akeso, Inc. is a Cayman Islands–incorporated company listed in Hong Kong, operating through a group structure referred to as the Group. While the announcement does not detail its specific business lines, the company positions itself as having strong research and development capabilities and a focus on long-term innovation-driven growth, suggesting a role in a technology or life sciences field. Average Trading Volume: 10,710,723 Technical Sentiment Signal: Sell Current Market Cap: HK$82.4B </div></div>

09926

Akeso Inc. (HK:9926) authorized HK$200 million to repurchase shares via its RSU scheme, citing undervaluation. Concurrently, executives plan up to HK$50 million in personal purchases to signal confidence. The company emphasizes long-term value and R&D strength, while analysts maintain a 'Hold' rating with a HK$130 target.

Akeso Launches HK$200 Million Share Purchase as Leadership Boosts Stakes